-
Diagnostics World | January’s funding focused on at-home cancer diagnostics, treatments for autoimmune disorders, and gene therapy for ophthalmology, Hepatitis B, and more.
Jan 29, 2025
-
Diagnostics World News | PathAI and Discovery Life Sciences launch partnership; new diagnostic tools for epilepsy, syphilis; OGT launches MRD panel; more.
Jan 28, 2025
-
Diagnostics World | At this year’s J.P. Morgan Healthcare Conference, Masoud Toloue, CEO of Quanterix, presented his company’s achievements of 2024, the acquisition of Akoya Biosciences, and their plans for the new year. Toloue opened with Quanterix’s mission, “The mission at Quanterix is to create the tools to enable discovery and better health.”
Jan 23, 2025
-
Diagnostics World | Researchers at the Tisch Cancer Institute at Mount Sinai, in collaboration with Memorial Sloan Kettering Cancer Center (MSKCC), have unveiled SCORPIO, an artificial intelligence (AI) tool designed to predict cancer patients’ responses to immune checkpoint inhibitor (ICI) therapy. By focusing on diagnostic capabilities, SCORPIO uses routine blood tests and clinical data to identify patterns that correlate with treatment outcomes, offering an innovative approach to guiding immunotherapy decisions.
Jan 22, 2025
-
Diagnostics World | PacBio’s president Christian Henry gave the sequencing company’s 43rd Annual J.P. Morgan Healthcare Conference address last week. And while Oxford Nanopore and Illumina both doubled down on proteomics and a multi-omic future, Henry stayed focus on PacBio’s mission to enable the promise of genomics to better human health.
Jan 21, 2025
-
Diagnostics World | Grail presented for the first time at the 42rd Annual J.P. Morgan Healthcare conference today, and Bob Ragusa, CEO, took the stage. Grail was divested from Illumina and became an independent, publicly traded company in June 2024. But while the company structure has changed significantly in 2024, the mission has not, Ragusa said: detecting cancer early, when it can be cured.
Jan 15, 2025
-
Diagnostics World | Among the many partnerships and technical announcements made by NVIDIA during the company's Monday morning presentation at the 43rd Annual J.P. Morgan Healthcare Conference, NVIDIA focused several on innovation within the healthcare and life sciences industry.
Jan 13, 2025
-
Diagnostics World | In the next phase of breath diagnostics, there is a promising area for future research: expanding upon the notion of “breath diagnostics” to leverage volatile organic compounds (VOCs) from elsewhere. VOCs from urine could be used to detect prostate cancer, for example. If looked at carefully with the right AI tools, leveraging VOCs could lead to compelling healthcare solutions down the road.
Jan 9, 2025
-
Diagnostics World | An international team of researchers hope to identify molecular and cellular level changes in muscle tissue that can be used to help diagnose and treat chronic fatigue syndrome (CFS) and long COVID. The quest is being pursued from both the physiological and electrical perspectives to better understand the muscle damage seen with the debilitating and still-mysterious conditions that share some striking similarities.
Jan 8, 2025